John E Milad, CEO of ERS Genomics, said: “The EPO’s decision to grant EP 4 289 948 with broad claims reinforces CVC’s leadership position in CRISPR IP in Europe and validates our strategic decision to self-revoke two legacy CRISPR/Cas9 patents. This decision provides our 150+ licensees with greater confidence in their rights, while maintaining CVC’s established patent leadership in Europe.”

“I am incredibly pleased that we are able to make SightScore clinically available in the U.S., marking a significant advancement in the fight against glaucoma,” said Nick Haan, CEO, Seonix Bio.

Late-breaking oral presentation features echocardiographic data analysis showing favorable impact of AVIM therapy on MODERATO II study patients with diastolic dysfunction, a key component in the development of heart failure.

This innovative digital companion system, seamlessly integrating hardware and software, will be designed to integrate with the Glooko platform, currently used by over 8,200 diabetes clinics worldwide. This integration will enable the capture and analysis of critical information related to injectable therapies from the Innovation Zed DOSE platform technology, offering enhanced support for healthcare providers and patients alike.

This partnership will blend Fore Genomics pediatric screening services with Inocras’s cutting-edge whole genome sequencing and bioinformatics platform, providing parents and healthcare providers with precise, personalized, and actionable insights into the genetic health of newborns and children, which can facilitate critical early diagnosis and proactive medical care.

“Our AI-powered pipeline represents a major leap forward for IPA,” said Dr. Jennifer Bath, CEO of ImmunoPrecise Antibodies. “By harnessing AI and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. This pipeline lays the foundation for groundbreaking advancements in therapeutic development, embodying our vision of innovation driven by clarity, precision, and purpose.”